America’s bungled response to the Covid-19 pandemic’s medical manufacturing demands illustrates the limitations of both the American industrial base and state capacity. Despite policies aimed at reshoring medical supply manufacturing, multiple projects’ funding expired before new facilities could be finished, limited federal resources were spread too thin, and the halting pace of policymaking failed to entice investors. An honest accounting of these policies’ failures and shortcomings is necessary to inform any serious response…

Read More